Linnaeus Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur

Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn of Escherichia coli (E. coli) on solid LB-agar media. Table 1 Table 1 RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category AIn an ex-vivo burn wound study, R327G showed a 4 to 5-log reduction (>99.99%) against Methicillin-re